Bristol Myers Squibb’s Devens site is becoming a cornerstone of its $30B cell therapy vision.

Bristol Myers Squibb’s (BMS) Devens site is becoming a cornerstone of its $30B cell therapy vision.
‍
🔷 Capital Expansion: Newly approved 244,000 ft² cell therapy facility.
🔷 Campus Size: 89-acre site operational for over a decade.
🔷 Focus: Commercial CAR T-cell therapy manufacturing.
🔷 Strategic Role: Anchors BMS’s expanding global cell therapy network.
🔷 Timeline: Facility came online in 2023 to meet growing commercial demand.
‍
PlantQuest Insight: CAR T therapy production combines clinical precision with industrial scale. Managing rapid scale-up across multi-building campuses demands a robust asset tracking network, asset hierarchies, and a CQV-ready digital infrastructure.

At PlantQuest, we’re proud to spotlight pioneering facilities like BMS Devens that are bringing breakthrough therapies to patients.